{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:39:38Z","timestamp":1792111178088,"version":"4.4.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"vor","delay-in-days":2496,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006314","name":"Biogen Idec","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006314","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1111\/jth.12911","type":"journal-article","created":{"date-parts":[[2015,4,23]],"date-time":"2015-04-23T05:20:52Z","timestamp":1429766452000},"page":"967-977","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":163,"title":["Recombinant factor\u00a0VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia\u00a0A"],"prefix":"10.1016","volume":"13","author":[{"given":"G.","family":"Young","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Mahlangu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Nolan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Liesner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Pasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Barnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Neelakantan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Gambino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.M.","family":"Cristiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.F.","family":"Pierce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/jth.12911_bb0010","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1055\/s-2004-815626","article-title":"Advances in care of children with hemophilia","volume":"29","author":"Manco-Johnson","year":"2003","journal-title":"Semin Thromb Hemost"},{"key":"10.1111\/jth.12911_bb0015","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJM200106073442307","article-title":"The hemophilias\u2014from royal genes to gene therapy","volume":"344","author":"Mannucci","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.12911_bb0020","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1056\/NEJMoa067659","article-title":"Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia","volume":"357","author":"Manco-Johnson","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.12911_bb0025","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1365-2796.1992.tb00546.x","article-title":"Twenty-five years' experience of prophylactic treatment in severe haemophilia\u00a0A and B","volume":"232","author":"Nilsson","year":"1992","journal-title":"J Intern Med"},{"key":"10.1111\/jth.12911_bb0030","unstructured":"National Hemophilia Foundation. Medical and Scientific Advisory Council (MASAC) recommendation concerning prophylaxis (regular administration of clotting factor concentrate to prevent bleeding), 2007. http:\/\/www.hemophilia.org\/NHFWeb\/MainPgs\/MainNHF.aspx?menuid=57{00AMP00}contentid=1007. Accessed 30 January 2015."},{"key":"10.1111\/jth.12911_bb0035","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/j.1365-2516.2001.00534.x","article-title":"Barriers to compliance with prophylaxis therapy in haemophilia","volume":"7","author":"Hacker","year":"2001","journal-title":"Haemophilia"},{"key":"10.1111\/jth.12911_bb0040","doi-asserted-by":"crossref","first-page":"e140","DOI":"10.1111\/j.1365-2516.2012.02770.x","article-title":"Treatment trends for haemophilia\u00a0A and haemophilia\u00a0B in the United States: results from the 2010 practice patterns survey","volume":"18","author":"Zappa","year":"2012","journal-title":"Haemophilia"},{"key":"10.1111\/jth.12911_bb0045","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1182\/asheducation-2011.1.397","article-title":"Biological rationale for new drugs in the bleeding disorders pipeline","volume":"2011","author":"Fogarty","year":"2011","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1111\/jth.12911_bb0050","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1182\/blood-2011-07-360594","article-title":"Population pharmacokinetics of recombinant factor\u00a0VIII: the relationships of pharmacokinetics to age and body weight","volume":"119","author":"Bjorkman","year":"2012","journal-title":"Blood"},{"key":"10.1111\/jth.12911_bb0055","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/jth.12076","article-title":"Biochemical and functional characterization of a recombinant monomeric factor\u00a0VIII Fc fusion protein","volume":"11","author":"Peters","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.12911_bb0060","article-title":"Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics","author":"Rath","year":"2013","journal-title":"Crit Rev Biotechnol"},{"key":"10.1111\/jth.12911_bb0065","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1182\/blood-2013-10-529974","article-title":"Phase\u00a03 study of recombinant factor\u00a0VIII Fc fusion protein in severe hemophilia\u00a0A","volume":"123","author":"Mahlangu","year":"2013","journal-title":"Blood"},{"key":"10.1111\/jth.12911_bb0070","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1182\/blood-2011-09-379453","article-title":"F8 gene mutation type and inhibitor development in patients with severe hemophilia\u00a0A: systematic review and meta-analysis","volume":"119","author":"Gouw","year":"2012","journal-title":"Blood"},{"key":"10.1111\/jth.12911_bb0075","doi-asserted-by":"crossref","first-page":"722","DOI":"10.3324\/haematol.12427","article-title":"The Italian AICE-Genetics hemophilia\u00a0A database: results and correlation with clinical phenotype","volume":"93","author":"Margaglione","year":"2008","journal-title":"Haematologica"},{"key":"10.1111\/jth.12911_bb0080","unstructured":"European Medicines Agency. Guideline on clinical investigation of recombinant and human plasma-derived factor\u00a0VIII products. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2011\/08\/WC500109692.pdf. Accessed 5 June 2014."},{"key":"10.1111\/jth.12911_bb0085","unstructured":"United States Food and Drug Administration. Guidance for industry: assay development for immunogenicity testing of therapeutic proteins. December 2009. http:\/\/www.fda.gov\/downloads\/Drugs\/Guidances\/UCM192750.pdf. Accessed 5 June 2014."},{"key":"10.1111\/jth.12911_bb0090","unstructured":"Baxter Healthcare Corporation. Advate [antihemophilic factor (recombinant), plasma\/albumin-free method] (package insert). July 2012. http:\/\/www.advate.com\/assets\/pdf\/advate_iri_pi.pdf. Accessed 17 July 2014."},{"key":"10.1111\/jth.12911_bb0095","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1111\/hae.12165","article-title":"Results from a large multinational clinical trial (guardian3) using prophylactic treatment with turoctocog alfa in paediatric patients with severe haemophilia\u00a0A: safety, efficacy and pharmacokinetics","volume":"19","author":"Kulkarni","year":"2013","journal-title":"Haemophilia"},{"key":"10.1111\/jth.12911_bb0100","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1182\/blood-2011-09-382846","article-title":"Safety and prolonged activity of recombinant factor\u00a0VIII Fc fusion protein in hemophilia\u00a0A patients","volume":"119","author":"Powell","year":"2012","journal-title":"Blood"},{"key":"10.1111\/jth.12911_bb0105","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/j.1538-7836.2011.04214.x","article-title":"A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study)","volume":"9","author":"Gringeri","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.12911_bb0110","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/j.1365-2516.2009.02186.x","article-title":"Physical activity for prevention of osteoporosis in patients with severe haemophilia on long-term prophylaxis","volume":"16","author":"Khawaji","year":"2010","journal-title":"Haemophilia"},{"key":"10.1111\/jth.12911_bb0115","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1542\/peds.2009-0072","article-title":"Athletic participation in severe hemophilia: bleeding and joint outcomes in children on prophylaxis","volume":"124","author":"Ross","year":"2009","journal-title":"Pediatrics"},{"key":"10.1111\/jth.12911_bb0120","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1046\/j.1365-2516.2002.00626.x","article-title":"Inhibitors: resolving diagnostic and therapeutic dilemmas","volume":"8","author":"DiMichele","year":"2002","journal-title":"Haemophilia"},{"key":"10.1111\/jth.12911_bb0125","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/j.1365-2141.2004.05058.x","article-title":"Efficacy and inhibitor development in previously treated patients with haemophilia\u00a0A switched to a B\u00a0domain-deleted recombinant factor\u00a0VIII","volume":"126","author":"Gringeri","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1111\/jth.12911_bb0130","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1111\/jth.12335","article-title":"Inhibitor development in previously treated hemophilia\u00a0A patients: a systematic review, meta-analysis, and meta-regression","volume":"11","author":"Xi","year":"2013","journal-title":"J Thromb Haemost"},{"issue":"Suppl. 1","key":"10.1111\/jth.12911_bb0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.12322","article-title":"The first recombinant FVIII produced in human cells\u2014an update on its clinical development programme","volume":"20","author":"Valentino","year":"2014","journal-title":"Haemophilia"},{"key":"10.1111\/jth.12911_bb0140","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s002770050179","article-title":"Antibodies to factor\u00a0VIII in plasma of patients with hemophilia\u00a0A and normal subjects","volume":"72","author":"Batlle","year":"1996","journal-title":"Ann Hematol"},{"key":"10.1111\/jth.12911_bb0145","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/j.1365-2516.2012.02903.x","article-title":"Antibody formation and specificity in Bethesda-negative brother pairs with haemophilia\u00a0A","volume":"19","author":"Klintman","year":"2013","journal-title":"Haemophilia"},{"key":"10.1111\/jth.12911_bb0150","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1182\/blood-2008-08-174987","article-title":"Quantitation of anti-factor\u00a0VIII antibodies in human plasma","volume":"113","author":"Krudysz-Amblo","year":"2009","journal-title":"Blood"},{"key":"10.1111\/jth.12911_bb0155","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1046\/j.1365-2141.1996.d01-1705.x","article-title":"High incidence of anti-FVIII antibodies against non-coagulant epitopes in haemophilia\u00a0A patients: a possible role for the half-life of transfused FVIII","volume":"93","author":"Dazzi","year":"1996","journal-title":"Br J Haematol"},{"key":"10.1111\/jth.12911_bb0160","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/bjh.12540","article-title":"Long-term anti-FVIII antibody response in Bethesda-negative haemophilia\u00a0A patients receiving continuous replacement therapy","volume":"163","author":"Klintman","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1111\/jth.12911_bb0165","first-page":"494","article-title":"Factor\u00a0VIII half-life and clinical phenotype of severe hemophilia\u00a0A","volume":"90","author":"van Dijk","year":"2005","journal-title":"Haematologica"},{"key":"10.1111\/jth.12911_bb0170","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s00228-009-0676-x","article-title":"Pharmacokinetics and dose requirements of factor\u00a0VIII over the age range 3\u201374\u00a0years: a population analysis based on 50 patients with long-term prophylactic treatment for haemophilia\u00a0A","volume":"65","author":"Bjorkman","year":"2009","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1111\/jth.12911_bb0175","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/j.1538-7836.2010.03757.x","article-title":"Comparative pharmacokinetics of plasma- and albumin-free recombinant factor\u00a0VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring","volume":"8","author":"Bjorkman","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.12911_bb0180","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2516.2009.02005.x","article-title":"Factor\u00a0VIII and von Willebrand factor interaction: biological, clinical and therapeutic importance","volume":"16","author":"Terraube","year":"2010","journal-title":"Haemophilia"},{"key":"10.1111\/jth.12911_bb0185","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-11-122945","article-title":"A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor","volume":"111","author":"Gallinaro","year":"2008","journal-title":"Blood"},{"key":"10.1111\/jth.12911_bb0190","first-page":"711.","article-title":"Effect of unstructured polypeptide insertions on the recombinant expression of human factor\u00a0VIII","volume":"11","author":"Kumar","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.12911_bb0195","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1182\/blood-2009-11-254755","article-title":"Rational design of a fully active, long-acting PEGylated factor\u00a0VIII for hemophilia\u00a0A treatment","volume":"116","author":"Mei","year":"2010","journal-title":"Blood"},{"key":"10.1111\/jth.12911_bb0200","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1111\/jth.12161","article-title":"Enhancing the pharmacokinetic properties of recombinant factor\u00a0VIII: first-in-man trial of glycoPEGylated recombinant factor\u00a0VIII in patients with hemophilia\u00a0A","volume":"11","author":"Tiede","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.12911_bb0205","first-page":"E35.","article-title":"Analysis of baseline characteristics and 5-day dosing interval\u00a0with rFVIIIFc in the phase\u00a03 A-LONG study","volume":"89","author":"Fogarty","year":"2014","journal-title":"Am J Hematol"},{"issue":"Suppl. 4","key":"10.1111\/jth.12911_bb0210","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1365-2516.2012.02824.x","article-title":"Clinical trial design in haemophilia","volume":"18","author":"DiMichele","year":"2012","journal-title":"Haemophilia"},{"key":"10.1111\/jth.12911_bb0215","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1182\/blood-2012-10-462200","article-title":"Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor\u00a0VIII variant","volume":"121","author":"McIntosh","year":"2013","journal-title":"Blood"},{"key":"10.1111\/jth.12911_bb0220","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1056\/NEJMoa1108046","article-title":"Adenovirus-associated virus vector-mediated gene transfer in hemophilia\u00a0B","volume":"365","author":"Nathwani","year":"2011","journal-title":"N Engl J Med"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjth.12911","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jth.12911","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jth.12911","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622127844?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622127844?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jth.12911","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:10:28Z","timestamp":1761534628000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622127844"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["S1538783622127844"],"URL":"https:\/\/doi.org\/10.1111\/jth.12911","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recombinant factor\u00a0VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia\u00a0A","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/jth.12911","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The Authors. Journal of Thrombosis and Haemostasis. Published by ELSEVIER INC. on behalf of International Society on Thrombosis and Haemostasis","name":"copyright","label":"Copyright"}]}}